Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice

Immunology Letters

Volumn 150, Issue 1-2, 2013, Pages 134-144

  Johnson, J Erik ^a   McNeil, Lisa K ^a   Megati, Shakuntala ^a   Witko, Susan E ^a   Roopchand, Vidia S ^a   Obregon, Jennifer H ^a   Illenberger, Deanne M ^a   Kotash, Cheryl S ^a   Nowak, Rebecca M ^a,b   Braunstein, Emily ^a,c   Yurgelonis, Irene ^a   Jansen, Kathrin U ^a   Kalyan, Narender K ^a   Sidhu, Maninder K ^a  

^a PFIZER INC   (United States)

^b Profectus BioSciences Inc   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

F protein; Neutralizing antibodies; Respiratory syncytial virus vaccines; Vesicular stomatitis virus vectors

Indexed keywords

CD107 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN 1 VECTOR; GLYCOPROTEIN RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN 3 VECTOR; GLYCOPROTEIN RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN 5 VECTOR; GLYCOPROTEIN RESPIRATORY SYNCYTIAL VIRUS GLYCOPROTEIN 3 VECTOR; GLYCOPROTEIN RESPIRATORY SYNCYTIAL VIRUS PROTEIN 3 VECTOR; HYBRID PROTEIN; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL A2 VIRUS VACCINE; RESPIRATORY SYNCYTIAL B VIRUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FUSION PROTEIN GENE; GENE EXPRESSION; GLYCOPROTEIN GENE; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH1 CELL; VACCINATION; VIRUS GENE; VIRUS LOAD;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GENE ORDER; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOLOGIC MEMORY; MICE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; TH1 CELLS; VESICULOVIRUS; VIRAL FUSION PROTEINS;

EID: 84874403780     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.12.005     Document Type: Article

References (92)

1. Chanock R.M., Parrott R.H. Acute respiratory disease in infancy and childhood: present understanding and prospects for prevention. Pediatrics 1965, 36:21-39.
2. Englund J.A., Sullivan C.J., Jordan M.C., Dehner L.P., Vercellotti G.M., Balfour H.H. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988, 109:203-208.
3. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759.
4. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
5. Han L.L., Alexander J.P., Anderson L.J. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999, 179:25-30.
6. Hall C.B., Geiman J.M., Biggar R., Kotok D.I., Hogan P.M., Douglas G.R. Respiratory syncytial virus infections within families. N Engl J Med 1976, 294:414-419.
7. Johnson K.M., Bloom H.H., Mufson M.A., Chanock R.M. Natural reinfection of adults by respiratory syncytial virus, Possible relation to mild upper respiratory disease. N Engl J Med 1962, 267:68-72.
8. Lee F.E., Walsh E.E., Falsey A.R., Betts R.F., Treanor J.J. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res 2004, 63:191-196.
9. Mills Jt, Van Kirk J.E., Wright P.F., Chanock R.M. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol 1971, 107:123-130.
10. Walsh E.E., Falsey A.R. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004, 190:373-378.
11. Walsh E.E., Falsey A.R. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol 2004, 73:295-299.
12. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
13. Saez-Llorens X., Moreno M.T., Ramilo O., Sanchez P.J., Top F.H., Connor E.M. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004, 23:707-712.
14. Piedra P.A. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J 2003, 22:S94-S99.
15. Meyer G., Deplanche M., Schelcher F. Human and bovine respiratory syncytial virus vaccine research and development. Comp Immunol Microbiol Infect Dis 2008, 31:191-225.
16. Belshe R.B., Anderson E.L., Walsh E.E. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993, 168:1024-1029.
17. Dudas R.A., Karron R.A. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998, 11:430-439.
18. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 1996, 14:1214-1218.
19. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997, 15:1130-1132.
20. Li X., Sambhara S., Li C.X., Ettorre L., Switzer I., Cates G., et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 2000, 269:54-65.
21. Li X., Sambhara S., Li C.X., Ewasyshyn M., Parrington M., Caterini J., et al. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med 1998, 188:681-688.
22. McKay E., Higgins P., Tyrrell D., Pringle C. Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J Med Virol 1988, 25:411-421.
23. Munoz F.M., Piedra P.A., Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003, 21:3465-3467.
24. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 1994, 32:13-36.
25. Pringle C.R., Filipiuk A.H., Robinson B.S., Watt P.J., Higgins P., Tyrrell D.A. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 1993, 11:473-478.
26. Tree J.A., Bembridge G., Hou S., Taylor G., Fashola-Stone E., Melero J., et al. An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung. Vaccine 2004, 22:2438-2443.
27. Tristram D.A., Welliver R.C., Mohar C.K., Hogerman D.A., Hildreth S.W., Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993, 167:191-195.
28. van Drunen Littel-van den Hurk S., Mapletoft J.W., Arsic N., Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 2007, 17:5-34.
29. Chen M., Hu K.F., Rozell B., Orvell C., Morein B., Liljestrom P. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 2002, 169:3208-3216.
30. Crowe J.E., Collins P.L., London W.T., Chanock R.M., Murphy B.R. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993, 11:1395-1404.
31. Elliott M.B., Chen T., Terio N.B., Chong S.Y., Abdullah R., Luckay A., et al. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 2007, 25:7132-7144.
32. Hsu K.H., Lubeck M.D., Davis A.R., Bhat R.A., Selling B.H., Bhat B.M., et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J Infect Dis 1992, 166:769-775.
33. Kahn J.S., Roberts A., Weibel C., Buonocore L., Rose J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 2001, 75:11079-11087.
34. Kahn J.S., Schnell M.J., Buonocore L., Rose J.K. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 1999, 254:81-91.
35. Martinez-Sobrido L., Gitiban N., Fernandez-Sesma A., Cros J., Mertz S.E., Jewell N.A., et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 2006, 80:1130-1139.
36. Olszewska W., Suezer Y., Sutter G., Openshaw P.J. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 2004, 23:215-221.
37. Schmidt A.C., McAuliffe J.M., Murphy B.R., Collins P.L. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 2001, 75:4594-4603.
38. Schmidt A.C., Wenzke D.R., McAuliffe J.M., St Claire M., Elkins W.R., Murphy B.R., et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 2002, 76:1089-1099.
39. Takimoto T., Hurwitz J.L., Zhan X., Krishnamurthy S., Prouser C., Brown B., et al. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol 2005, 18:255-266.
40. Tang R.S., MacPhail M., Schickli J.H., Kaur J., Robinson C.L., Lawlor H.A., et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 2004, 78:11198-11207.
41. Wyatt L.S., Whitehead S.S., Venanzi K.A., Murphy B.R., Moss B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 1999, 18:392-397.
42. Xiang Z., Li Y., Gao G., Wilson J.M., Ertl H.C. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. J Immunol 2003, 171:4287-4293.
43. Clarke D.K., Cooper D., Egan M.A., Hendry R.M., Parks C.L., Udem S.A. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol 2006, 28:239-253.
44. Roberts A., Buonocore L., Price R., Forman J., Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 1999, 73:3723-3732.
45. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998, 72:4704-4711.
46. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005, 340:174-182.
47. Schlereth B., Rose J.K., Buonocore L., ter Meulen V., Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 2000, 74:4652-4657.
48. Natuk R.J., Cooper D., Guo M., Calderon P., Wright K.J., Nasar F., et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 2006, 80:4447-4457.
49. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005, 11:786-790.
50. Rose N.F., Roberts A., Buonocore L., Rose J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 2000, 74:10903-10910.
51. Clarke D.K., Nasar F., Lee M., Johnson J.E., Wright K., Calderon P., et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol 2007, 81:2056-2064.
52. Johnson J.E., Nasar F., Coleman J.W., Price R.E., Javadian A., Draper K., et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007, 360:36-49.
53. Jeetendra E., Ghosh K., Odell D., Li J., Ghosh H.P., Whitt M.A. The membrane-proximal region of vesicular stomatitis virus glycoprotein G ectodomain is critical for fusion and virus infectivity. J Virol 2003, 77:12807-12818.
54. Jeetendra E., Robison C.S., Albritton L.M., Whitt M.A. The membrane-proximal domain of vesicular stomatitis virus G protein functions as a membrane fusion potentiator and can induce hemifusion. J Virol 2002, 76:12300-12311.
55. Robison C.S., Whitt M.A. The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. J Virol 2000, 74:2239-2246.
56. Witko S.E., Johnson J.E., Kalyan N.K., Felber B.K., Pavlakis G.N., Sidhu M.K., et al. Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression. J Virol Methods 2010, 164:43-50.
57. Abraham G., Banerjee A.K. Sequential transcription of the genes of vesicular stomatitis virus. Proc Natl Acad Sci U S A 1976, 73:1504-1508.
58. Ball L.A., White C.N. Order of transcription of genes of vesicular stomatitis virus. Proc Natl Acad Sci U S A 1976, 73:442-446.
59. Cooper D., Wright K.J., Calderon P.C., Guo M., Nasar F., Johnson J.E., et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008, 82:207-219.
60. Ramsburg E., Publicover J., Buonocore L., Poholek A., Robek M., Palin A., et al. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J Virol 2005, 79:15043-15053.
61. Villarreal L.P., Breindl M., Holland J.J. Determination of molar ratios of vesicular stomatitis virus induced RNA species in BHK21 cells. Biochemistry 1976, 15:1663-1667.
62. Schnell M.J., Johnson J.E., Buonocore L., Rose J.K. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 1997, 90:849-857.
63. Hancock G.E., Smith J.D., Heers K.M. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus. J Infect Dis 2000, 181:1768-1771.
64. Schnell M.J., Buonocore L., Whitt M.A., Rose J.K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 1996, 70:2318-2323.
65. Lindell D.M., Ballinger M.N., McDonald R.A., Toews G.B., Huffnagle G.B. Diversity of the T-cell response to pulmonary Cryptococcus neoformans infection. Infect Immun 2006, 74:4538-4548.
66. Hancock G.E., Speelman D.J., Heers K., Bortell E., Smith J., Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 1996, 70:7783-7791.
67. Hancock G.E., Speelman D.J., Frenchick P.J., Mineo-Kuhn M.M., Baggs R.B., Hahn D.J. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine 1995, 13:391-400.
68. Zielinska E., Liu D., Wu H.Y., Quiroz J., Rappaport R., Yang D.P. Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis. Virol J 2005, 2:84.
69. Yoder S.M., Zhu Y., Ikizler M.R., Wright P.F. Role of complement in neutralization of respiratory syncytial virus. J Med Virol 2004, 72:688-694.
70. Karron R.A., Wright P.F., Crowe J.E., Clements-Mann M.L., Thompson J., Makhene M., et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997, 176:1428-1436.
71. Whitehead S.S., Hill M.G., Firestone C.Y., St Claire M., Elkins W.R., Murphy B.R., et al. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol 1999, 73:9773-9780.
72. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe J.E., Boyce T.G., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000, 182:1331-1342.
73. Hancock G.E., Smith J.D., Heers K.M. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12. Viral Immunol 2000, 13:57-72.
74. Paradiso P.R., Hu B.T., Arumugham R., Hildreth S. Mapping of a fusion related epitope of the respiratory syncytial virus fusion protein. Vaccine 1991, 9:231-237.
75. Walsh E.E., Hruska J. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol 1983, 47:171-177.
76. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
77. Collarini E.J., Lee F.E., Foord O., Park M., Sperinde G., Wu H., et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 2009, 183:6338-6345.
78. Haynes L.M., Caidi H., Radu G.U., Miao C., Harcourt J.L., Tripp R.A., et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 2009, 200:439-447.
79. Miao C., Radu G.U., Caidi H., Tripp R.A., Anderson L.J., Haynes L.M. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol 2009, 90:1119-1123.
80. Zhong X., Lu Z., Zollner R., Zhang J., Braunstein E., Kalyan N., et al. Developing stable cell lines for the production of vaccine antigens. Development of vaccines: from discovery to clinical testing 2011, 243-259. John Wiley & Sons, Hoboken, NJ USA. M. Singh, I.K. Srivastava (Eds.).
81. Falsey A.R., Singh H.K., Walsh E.E. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006, 78:1493-1497.
82. Henderson F.W., Collier A.M., Clyde W.A., Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979, 300:530-534.
83. Gardner E.M., Murasko D.M. Age-related changes in Type 1 and Type 2 cytokine production in humans. Biogerontology 2002, 3:271-290.
84. Effros R.B., Boucher N., Porter V., Zhu X., Spaulding C., Walford R.L., et al. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 1994, 29:601-609.
85. Looney R.J., Falsey A.R., Walsh E., Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J Infect Dis 2002, 185:682-685.
86. Miller R.A. The aging immune system: primer and prospectus. Science 1996, 273:70-74.
87. Wick G., Jansen-Durr P., Berger P., Blasko I., Grubeck-Loebenstein B. Diseases of aging. Vaccine 2000, 18:1567-1583.
88. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969, 89:449-463.
89. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969, 89:435-448.
90. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
91. Johnson J.E., Coleman J.W., Kalyan N.K., Calderon P., Wright K.J., Obregon J., et al. In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation. Vaccine 2009, 27:2930-2939.
92. Graham B.S., Henderson G.S., Tang Y.W., Lu X., Neuzil K.M., Colley D.G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993, 151:2032-2040.